101 related articles for article (PubMed ID: 16224510)
1. Going against the flow: the impact of PHARMAC not funding COX-2 inhibitors for chronic arthritis.
Grocott R; Metcalfe S
N Z Med J; 2005 Oct; 118(1223):U1690. PubMed ID: 16224510
[TBL] [Abstract][Full Text] [Related]
2. PHARMAC responds on TNF inhibitors for inflammatory arthritis.
Metcalfe S; Moodie P; Grocott R; Wilkinson T
N Z Med J; 2005 Dec; 118(1227):U1799. PubMed ID: 16372039
[No Abstract] [Full Text] [Related]
3. Merck responds to PHARMAC's article on COX-2 inhibitors.
Woolner D
N Z Med J; 2005 Nov; 118(1225):U1746. PubMed ID: 16286953
[No Abstract] [Full Text] [Related]
4. PHARMAC and lack of funding for clopidogrel.
White H; Ellis C
N Z Med J; 2005 Jan; 119(1228):U1808. PubMed ID: 16462916
[TBL] [Abstract][Full Text] [Related]
5. PHARMAC responds on long-acting insulin analogues.
Metcalfe S; Evans J; Moodie P
N Z Med J; 2005 Oct; 118(1224):U1716. PubMed ID: 16258585
[No Abstract] [Full Text] [Related]
6. Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: what is the potential impact of the withdrawal of rofecoxib?
Rahme E; Hunsche E; Toubouti Y; Chabot I
Arthritis Rheum; 2006 Feb; 55(1):27-34. PubMed ID: 16463408
[TBL] [Abstract][Full Text] [Related]
7. New Zealand cancer patients should have access to erythropoietin treatment.
Carter J; Clay J
N Z Med J; 2006 May; 119(1234):U1989. PubMed ID: 16718300
[TBL] [Abstract][Full Text] [Related]
8. What happened to the prescribing of other COX-2 inhibitors, paracetamol and non-steroidal anti-inflammatory drugs when rofecoxib was withdrawn in Australia?
Barozzi N; Tett SE
Pharmacoepidemiol Drug Saf; 2007 Nov; 16(11):1184-91. PubMed ID: 17636557
[TBL] [Abstract][Full Text] [Related]
9. PHARMAC and Herceptin for early-stage breast cancer in New Zealand: Herceptin or deception?
Rosevear M
N Z Med J; 2006 Jun; 119(1235):U2014. PubMed ID: 16751832
[TBL] [Abstract][Full Text] [Related]
10. PHARMAC not funding some treatments for rare, life-threatening diseases: bosentan as an example.
Whyte K
N Z Med J; 2005 Nov; 118(1226):U1759. PubMed ID: 16311607
[TBL] [Abstract][Full Text] [Related]
11. Interferon beta, PHARMAC, and political directives: in the best interests of people with multiple sclerosis?
McNaughton H; Kayes N; McPherson K
N Z Med J; 2006 Apr; 119(1232):U1939. PubMed ID: 16633398
[TBL] [Abstract][Full Text] [Related]
12. Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand.
Raftery JP
Med J Aust; 2008 Jan; 188(1):26-8. PubMed ID: 18205559
[TBL] [Abstract][Full Text] [Related]
13. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
Spalding WM; Reeves MJ; Whelton A
Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
[TBL] [Abstract][Full Text] [Related]
14. Applying Programme Budgeting Marginal Analysis in the health sector: 12 years of experience.
Grocott R
Expert Rev Pharmacoecon Outcomes Res; 2009 Apr; 9(2):181-7. PubMed ID: 19402806
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of nonsteroidal anti-inflammatory drug strategies in rheumatoid arthritis.
Inotai A; Mészáros A
Int J Technol Assess Health Care; 2009 Apr; 25(2):190-5. PubMed ID: 19366498
[TBL] [Abstract][Full Text] [Related]
16. PHARMAC responds on agents to prevent osteoporotic fractures.
Metcalfe S; Wilkinson T; Rasiah D
N Z Med J; 2006 Mar; 119(1230):U1895. PubMed ID: 16532056
[No Abstract] [Full Text] [Related]
17. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
Gislason GH; Jacobsen S; Rasmussen JN; Rasmussen S; Buch P; Friberg J; Schramm TK; Abildstrom SZ; Køber L; Madsen M; Torp-Pedersen C
Circulation; 2006 Jun; 113(25):2906-13. PubMed ID: 16785336
[TBL] [Abstract][Full Text] [Related]
18. Therapy switching and associated costs in elderly patients receiving COX-2 selective inhibitors or non-selective non-steroidal anti-inflammatory drugs in Quebec, Canada.
Rahme E; Toubouti Y; Hunsche E
Rheumatology (Oxford); 2006 Jul; 45(7):903-10. PubMed ID: 16461440
[TBL] [Abstract][Full Text] [Related]
19. PHARMAC measures savings elsewhere to the health sector.
Metcalfe S; Dougherty S; Brougham M; Moodie P
N Z Med J; 2003 Mar; 116(1170):U362. PubMed ID: 12658320
[No Abstract] [Full Text] [Related]
20. Designed delays versus rigorous pragmatic trials: lower carat gold standards can produce relevant drug evaluations.
Maclure M; Carleton B; Schneeweiss S
Med Care; 2007 Oct; 45(10 Supl 2):S44-9. PubMed ID: 17909382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
